Merck Ends Revolution Medicines Talks; Nvidia Invests $2B in CoreWeave; US Rare Earth Funding

Merck's Acquisition Talks with Revolution Medicines

• 💡 Merck has ended negotiations to acquire Revolution Medicines due to a disagreement on price, as reported by The Wall Street Journal.
• 🎯 The potential deal was valued at approximately $30 billion for Revolution Medicines.
• ⚠️ Talks could potentially restart, or another buyer might emerge for Revolution Medicines.
• 🚀 Merck is actively seeking acquisitions to bolster its treatment portfolio and offset anticipated patent losses.

US Rare Earth Secures Significant Funding

• ⚡ USA Rare Earth announced a non-binding letter of intent with the US Department of Commerce for $1.6 billion in funding.
• 🇺🇸 This funding aims to accelerate domestic production of key rare earth elements, reducing reliance on China.
• 📈 In addition to government funding, USA Rare Earth also secured $1 billion in private investment.
• 📊 The company's stock saw a significant rise, though its financials suggest it is a concept stock.

Nvidia's Expanded Investment in CoreWeave

• 🧠 Nvidia is investing an additional $2 billion into CoreWeave, a company specializing in AI computing capacity.
• 🚀 This investment will help CoreWeave expand its AI computing capacity to over 5 gigawatts by 2030.
• 💻 As part of the agreement, CoreWeave will be among the first to deploy new Nvidia products, including storage systems and a new CPU.
• 🤝 This deepens the existing partnership, with Nvidia previously agreeing to purchase over $6 billion in services from CoreWeave through 2032.
• 📈 CoreWeave's IPO shareholders have seen substantial returns, with the stock trading significantly higher than its March 2025 IPO price.